Related Experiment Video
Updated: May 31, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
SphB1 export system for antigen presentation to the respiratory tract by a live pertussis vaccine
Lazara Elena Santiesteban-Lores1, Dominique Raze1, Violaine Dubois1,2
1University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL - Centre for Infection and Immunity of Lille, 1, Rue du Prof, F-59019, Calmette, Lille, France.
Abstract:
BPZE1 is a live attenuated vaccine currently in advanced clinical development for nasal immunization against pertussis. The ability of this vaccine to induce mucosal and systemic, humoral and cellular immunity make it an attractive mucosal delivery system for heterologous antigens to induce immunity especially in the respiratory tract. Here, we have developed a heterologous antigen expression system based on the pertactin-deficient BPZE1 derivative IB-V002 by using the SphB1 secretion system to present the SARS-CoV-2 nucleocapsid protein (N) as a model antigen to the respiratory mucosa. SphB1 is an autotransporter comprising a subtilisin-like passenger domain and a C-terminal ß-barrel domain. The passenger domain was replaced by the SARS-CoV-2 N protein. The recombinant gene was inserted into the urease locus of IB-V002 and placed under the control of the pertactin promoter and signal peptide. Immunoblot analyses indicated that the chimeric protein was produced and secreted by the recombinant strain named BT-V101. Mice intranasally immunized with BT-V101 induced N-specific IgG in serum and IFN-γ production by spleen cells. Importantly, a local N-specific CD8+ T cell response was observed in nose-associated lymphoid tissues by MHC class I tetramer staining. Additionally, immunization with BT-V101 efficiently primed mice to recombinant purified N protein given as a boost either intranasally or subcutaneously. These results demonstrate the suitability of the B. pertussis SphB1 secretion machinery to secret heterologous antigens for the development of a mucosal immunization vaccine platform with the induction of specific humoral and cellular, local, and systemic immune responses. KEY POINTS: • The SphB1 export system was used to secrete heterologous antigens by B. pertussis. • Recombinant B. pertussis induced systemic and local immunity to foreign antigens. • Recombinant B. pertussis efficiently primed immune responses to foreign antigens.
Related Concept Videos
Respiratory Syncytial Virus Disease
Regulation of Bacterial Virulence
Diphtheria
Vaccinations
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...

